Compare iShares Core MSCI EAFE ETF (IEFA) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Illumina, Inc. — how do they compare? iShares Core MSCI EAFE ETF trades at $96.56 (market cap $189.19B), while Illumina, Inc. trades at $278.09 (market cap $39.95B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 4.7× Illumina, Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, iShares Core MSCI EAFE ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 40 Days and Illumina, Inc. for 83 Days on average.
| IEFA | ILMN | |
|---|---|---|
Market Cap | $189.19B | $39.95B |
Volume | 8,441,787 | 3,169,503 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $293.69 |
52-Week Low | $85.06 | $91.00 |
Typical Hold Time | 40 Days | 83 Days |
Enterprise Value | — | $41.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $96.37, up 0.18% on the day, while technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The fund provides exposure to developed markets outside North America, holding $196 billion in assets. Recent news highlights its role in international diversification strategies and comparisons with competing ETFs like Schwab's SCHF and State Street's SPDW.
The outlook for IEFA is influenced by global market sentiment and interest rate uncertainty, offering diversification benefits but facing headwinds from geopolitical tensions. Key risks include concentration in developed economies and currency fluctuations. Analyst comparisons favor IEFA for its scale and dividend yield, though expense ratios and performance relative to peers remain considerations for investors.
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
